Marksans Pharma Ltd
Marksans Pharma Ltd (MARKSANS) last reported results for the quarter ended Jun 2026, with sales of ₹841 crore and net profit of ₹159 crore. The stock last traded at ₹341, a market capitalisation of ₹15,444 crore, on a P/E of 29.9. Over the past 52 weeks the stock has ranged between ₹155 and ₹351. Figures are as of 6 Oct 2026 and are not real time.
Marksans Pharma Ltd share price and key metrics
- Current price
- ₹341
- Market cap
- ₹15,444 cr
- Stock P/E
- 29.9
- Book value
- ₹66.7
- ROE
- 15.2%
- ROCE
- 18.8%
- Dividend yield
- 0.27%
- 52w high / low
- 351/155
Metrics as of 6 Oct 2026. Not real time.
Track Marksans Pharma Ltd
Cruxal reads every Marksans Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Marksans Pharma Ltd growth and returns
- 10 Years
- 13%
- 5 Years
- 16%
- 3 Years
- 17%
- TTM
- 20%
- 10 Years
- 18%
- 5 Years
- 12%
- 3 Years
- 16%
- TTM
- 48%
- 10 Years
- 20%
- 5 Years
- 36%
- 3 Years
- 45%
- 1 Year
- 102%
- 10 Years
- 17%
- 5 Years
- 17%
- 3 Years
- 16%
- Last Year
- 15%
Marksans Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹841 cr, up 35.6% from ₹620 cr a year earlier. Net profit was ₹159 cr, up 174.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 642 | 682 | 708 | 620 | 720 | 754 | 856 | 841 |
| Expenses | 495 | 543 | 582 | 520 | 576 | 594 | 661 | 628 |
| Operating profit | 147 | 139 | 127 | 100 | 144 | 161 | 195 | 213 |
| OPM % | 23% | 20% | 18% | 16% | 20% | 21% | 23% | 25% |
| Other income | -0 | 28 | 15 | 6 | 22 | 20 | 35 | 25 |
| Interest | 3 | 3 | 3 | 6 | 6 | 6 | 6 | 7 |
| Depreciation | 20 | 21 | 23 | 23 | 27 | 24 | 24 | 25 |
| Profit before tax | 125 | 143 | 116 | 77 | 133 | 151 | 200 | 207 |
| Tax % | 22% | 27% | 22% | 24% | 26% | 25% | 25% | 23% |
| Net profit | 98 | 105 | 91 | 58 | 99 | 114 | 149 | 159 |
| EPS (₹) | 2.13 | 2.31 | 2.00 | 1.29 | 2.17 | 2.50 | 3.27 | 3.47 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Marksans Pharma Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 767 | 913 | 1,000 | 1,134 | 1,376 | 1,491 | 1,852 | 2,177 | 2,623 | 2,951 | 3,172 |
| Operating profit | 45 | 78 | 132 | 192 | 340 | 259 | 340 | 459 | 533 | 601 | 714 |
| OPM % | 6% | 9% | 13% | 17% | 25% | 17% | 18% | 21% | 20% | 20% | 22% |
| Net profit | 11 | 36 | 80 | 121 | 239 | 187 | 265 | 315 | 383 | 420 | 521 |
| EPS (₹) | 0.22 | 0.80 | 1.87 | 2.95 | 5.76 | 4.51 | 5.88 | 6.92 | 8.40 | 9.22 | 11.41 |
TTM is the trailing twelve months to the most recent quarter.
Marksans Pharma Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 41 | 41 | 41 | 41 | 41 | 41 | 45 | 45 | 45 | 45 |
| Reserves | 392 | 430 | 502 | 595 | 846 | 1,161 | 1,700 | 2,020 | 2,422 | 2,978 |
| Borrowings | 110 | 118 | 100 | 30 | 34 | 111 | 123 | 244 | 322 | 343 |
| Other liabilities | 209 | 142 | 160 | 236 | 307 | 323 | 322 | 372 | 451 | 489 |
| Total liabilities | 752 | 731 | 802 | 902 | 1,228 | 1,636 | 2,190 | 2,681 | 3,240 | 3,856 |
| Fixed assets | 267 | 279 | 270 | 303 | 309 | 428 | 486 | 776 | 982 | 1,044 |
| CWIP | 0 | 0 | 0 | 0 | 12 | 3 | 10 | 9 | 27 | 59 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 27 | 1 | 0 |
| Other assets | 484 | 451 | 533 | 599 | 907 | 1,205 | 1,694 | 1,869 | 2,230 | 2,753 |
| Total assets | 752 | 731 | 802 | 902 | 1,228 | 1,636 | 2,190 | 2,681 | 3,240 | 3,856 |
As reported by the company. Total assets equal total liabilities by construction.
Marksans Pharma Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 14 | 50 | 27 | 233 | 179 | 99 | 237 | 230 | 207 | 458 |
| Cash from investing | -21 | -39 | -13 | -60 | -45 | -84 | -259 | -141 | -49 | -249 |
| Cash from financing | -3 | 3 | -21 | -114 | -15 | 80 | 198 | -69 | -65 | -71 |
| Net cash flow | -10 | 15 | -7 | 60 | 118 | 94 | 176 | 21 | 93 | 138 |
| Free cash flow | -14 | 11 | 14 | 174 | 133 | 53 | 184 | 22 | 35 | 329 |
| CFO / operating profit | 31% | 73% | 41% | 134% | 67% | 66% | 88% | 77% | 62% | 99% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Marksans Pharma Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 4% | 10% | 18% | 25% | 38% | 23% | 22% | 21% | 20% | 19% |
| Debtor days | 118 | 71 | 64 | 78 | 72 | 97 | 82 | 76 | 75 | 80 |
| Inventory days | 151 | 152 | 215 | 155 | 248 | 216 | 192 | 217 | 270 | 278 |
| Days payable | 129 | 54 | 78 | 71 | 103 | 102 | 91 | 94 | 98 | 96 |
| Cash conversion cycle | 140 | 169 | 202 | 163 | 217 | 211 | 183 | 199 | 247 | 261 |
| Working capital days | 77 | 70 | 97 | 87 | 104 | 121 | 122 | 129 | 142 | 149 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Marksans Pharma Ltd shareholding pattern
Promoters held 43.87% at Jun 2026, broadly unchanged since Jun 2025. FIIs 17.47% and DIIs 6.19%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% |
| FIIs | 21.31% | 21.95% | 22.19% | 19.89% | 16.92% | 8.13% | 16.76% | 17.47% |
| DIIs | 4.10% | 4.30% | 4.55% | 5.50% | 5.28% | 5.91% | 6.57% | 6.19% |
| Public | 30.70% | 29.88% | 29.37% | 30.74% | 33.93% | 42.08% | 32.78% | 32.46% |
| No. of shareholders | 2,48,845 | 2,59,813 | 2,57,273 | 2,56,221 | 2,65,788 | 2,55,153 | 2,46,279 | 2,46,635 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Marksans Pharma Ltd corporate filings
- Intimation of Closure of Trading Window for the quarter and half year ended 30 September, 2026Insider Trading / SASTlow impact
- Marksans Pharma Ltd announces special window for re-lodgement of physical share transfer requestsCompany Updatelow impact
Cruxal's analysis: Marksans Pharma has issued a notice to shareholders regarding the re-opening of a special…
Read the full analysis - Marksans Pharma Ltd. issues newspaper notice regarding transfer of unclaimed dividends and equity shares to IEPFCompany Updatelow impact
Cruxal's analysis: Marksans Pharma Ltd. has published a mandatory public notice in English and Marathi…
Read the full analysis - Marksans Pharma Ltd schedules investor meetingCompany Updatelow impact
Cruxal's analysis: Marksans Pharma Ltd has issued an intimation regarding a scheduled analyst/investor…
Read the full analysis - Marksans Pharma Limited concludes 34th AGM; shareholders approve final dividend of INR 0.90 per shareAGM/EGMlow impact
Cruxal's analysis: Marksans Pharma Limited has successfully concluded its 34th Annual General Meeting, with…
Read the full analysis - Marksans Pharma Limited Concludes 34th Annual General Meeting; Shareholders Approve Dividend of INR 0.90 Per ShareAGM/EGMlow impact
Cruxal's analysis: Marksans Pharma Limited has successfully concluded its 34th Annual General Meeting, where…
Read the full analysis - Marksans Pharma Ltd discloses ESG rating reportCompany Updatelow impact
Cruxal's analysis: Marksans Pharma Ltd has submitted a disclosure regarding its ESG (Environmental, Social…
Read the full analysis - Marksans Pharma reports strong Q1 FY27 with 35.6% revenue growth and record EBITDA of INR213 croreCompany Updatehigh impact
Cruxal's analysis: Marksans Pharma delivered a robust Q1 FY27 performance, reporting revenue of INR841 crore…
Read the full analysis - Marksans Pharma Ltd. uploads audio recording of Q1FY27 earnings conference callCompany Updatelow impact
Cruxal's analysis: Marksans Pharma Ltd. has formally complied with SEBI disclosure requirements by uploading…
Read the full analysis - Marksans Pharma Ltd. Reports Strong Q1 FY27 Financial Results with Significant YoY GrowthCompany Updatehigh impact
Cruxal's analysis: Marksans Pharma Ltd. has released its unaudited financial results for the quarter ended…
Read the full analysis - Marksans Pharma Reports Strong Q1FY27 Results with 174% YoY PAT Growth and Record Cash Balance of 1,058 croreCompany Updatehigh impact
Cruxal's analysis: Marksans Pharma Ltd. delivered a robust performance for Q1FY27, with operating revenue…
Read the full analysis - Marksans Pharma Reports Strong Q1 FY27 Results with 173.9% YoY PAT Growth and Strategic European ExpansionCompany Updatehigh impact
Cruxal's analysis: Marksans Pharma Limited delivered a robust performance in Q1 FY27, reporting revenue of…
Read the full analysis - Marksans Pharma Reports Strong Q1 FY27 Consolidated Profit Growth of 173.7% YoY; Expands European Footprint via AcquisitionsBoard Meetinghigh impact
Cruxal's analysis: Marksans Pharma Limited delivered a robust performance for the quarter ended 30 June…
Read the full analysis - Marksans Pharma Ltd announces newspaper publication for Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Marksans Pharma Ltd has fulfilled regulatory requirements under Regulation 30 of the SEBI…
Read the full analysis - Marksans Pharma Ltd files routine Business Responsibility and Sustainability Report (BRSR)Otherslow impact
Cruxal's analysis: Marksans Pharma Ltd has submitted its Business Responsibility and Sustainability Report…
Read the full analysis - Marksans Pharma Ltd files Annual Report for Financial Year 2025-26Otherslow impact
Cruxal's analysis: Marksans Pharma Ltd has submitted its Annual Report for the Financial Year 2025-26 to the…
Read the full analysis - Marksans Pharma Ltd. Announces 34th AGM, Proposes ₹0.90 Final Dividend for FY26, and Seeks Approval for Director Re-appointmentsAGM/EGMmedium impact
Cruxal's analysis: Marksans Pharma Ltd. has announced its 34th Annual General Meeting (AGM) to be held on…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.